The highest score in the Prescription Justice Congressional Report Card on Drug Prices – 100 – goes to Representative Jan Schakowsky (D-IL), with a grade of A+. The only other A+ in the House goes to Rep. Perter Welch (D-VT), who landed a score of 99.5.
Rep. Tom Malinowski (D-NJ7) is one of a very small number of members of the U.S. House of Representatives to receive an A- in our Congressional Report Card on Drug Prices. Only 16 other House members received an A-, A or A+. The congressman’s high grade is based on his voting record and because he has taken the Prescription Justice Pledge, proclaiming support for the Prescription Justice Policy Platform on lowering drug prices. We applaud Rep. Malisnowski for his actions to help end the crisis of high drug prices in America!
Prescription Justice is pleased to announce that Isaiah Cochran, MD has been appointed to the Prescription Justice Board of Directors.
Dr. Cochran is the immediate past president and chair of the board of trustees for the American Medical Student Association (AMSA). He served as a key organizational spokesperson for AMSA and as an active promoter of the organization's educational programming, advocacy pursuits, and membership recruitment and engagement efforts.
Prescription Justice has graded all members of Congress in a drug prices report card. Some people are dismayed that Speaker Nancy Pelosi received an F. After all, didn’t she roll-out and shepherd H.R. 3, the Elijah Cummings Lower Drug Costs Now Act, through the House and vociferously called for its passage on the House floor, as read on the Speaker’s website. So, what happened to her grade? A lot of Rep. Pelosi’s F has to do with her role as Speaker and how it differs from all other legislators.
While the coronavirus pandemic is the most pernicious public health crisis of our time, for decades now the crisis of high drug prices is a ubiquitous feature of the American healthcare landscape. Young adults dying because they can’t afford insulin; people burdened with battling cancer facing bankruptcy due to the price of cancer drugs; patients going to the emergency rooms because they did not take heart medications due to cost; parents faced with the decision of whether or not they can afford a new Epipen, as their old one faces expiration, and the list goes on and on. We are outraged by the greed of the pharmaceutical industry, but we cannot vote in and out of office their CEOs and other executives. But we can do just that when it comes to Congress. To help, Prescription Justice has created the Drug Prices Congressional Report Card in which we have graded all members of the U.S. Congress, House and Senate, on their action or inaction on drug prices.